로딩 중…
지수 로딩 중…
퀀타매트릭스
317690· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,625-6.25%
2026-06-19
Price Chart
퀀타매트릭스-10.71%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 52.85B KRW |
| Revenue | 3.40B KRW |
| Net Income | -19.98B KRW |
| Total Assets | 47.87B KRW |
| Net Assets | 35.90B KRW |
| Employees | 91 |
| Value | |
| P/B | 1.47x |
| P/S | 15.56x |
| FCF Yield | -28.51% |
| Profitability | |
| ROE | -55.66% |
| ROA | -41.74% |
| Op. Margin | -465.42% |
| Revenue Growth | -28.69% |
| Financial Health | |
| Debt Ratio | 133.35% |
| Total Debt | 7.62B KRW |
| FCF | -15.07B KRW |
| Cash | 13.00B KRW |
| Current Ratio | 4.12x |
| Performance | |
| 1Y Return | -10.71% |
| 1M Return | -19.85% |
| From 52W High | -59.92% |
| 1Y MDD | -53.70% |
| Trading | |
| Volume | 158,040 shares |
| Foreign Own. | 18.75% |
| Per Share | |
| EPS | -1,038 KRW |
| BPS | 1,783 KRW |
Company Info
Established in 2010 and listed on KOSDAQ in 2020, this company specializes in in vitro diagnostic medical devices. It develops microbial diagnostic technology-based testing systems (dRAST, QDST), molecular immunology platforms (QMAP), and automation equipment (QMIA), which are sold to advanced general hospitals both domestically and internationally. The company is also developing the uCIA system and pursuing the commercialization of the QPLEX Alz plus Assay kit for early diagnosis of Alzheimer's disease. Quantamatrix, established in 2010, is headquartered in Seoul Metropolitan City, Geumcheon-gu.